Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease. Results of a pilot trial

Drugs in R and D

Volumn 5, Issue 4, 2004, Pages 185-190

  Ragozzino, Giovanni ^a   Mattera, Edi ^a   Madrid, Elisa ^a   Salomone, Patrizia ^a   Fasano, Carmela ^a   Gioia, Filomena ^a   Acerra, Giusy ^a   del Guercio, Raffaele ^a   Federico, Pasquale ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BENZOIC ACID DERIVATIVE; BIGUANIDE DERIVATIVE; C PEPTIDE; CHOLESTEROL; FIBRINOGEN; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PROPIONYLCARNITINE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLAUDICATION; CLINICAL ARTICLE; DIABETIC ANGIOPATHY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; LOW CALORY DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; WALKING;

BLOOD GLUCOSE; CARNITINE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PILOT PROJECTS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 4143079204     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405040-00001     Document Type: Article

References (29)

1. Hiatt WR, Marshall GA, Baxter J. Diagnostic methods for peripheral artery disease in San Louis Valley Diabetes study. J Clin Epidemiol 1990; 43: 597-606
2. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510-5
3. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from disease, injuries, and risk factor in 1990 and projected to 2020. Geneva: World Health Organization, 1996
4. Broderick TL, Driedzic W, Paulson DJ. Propionyl-L-carnitine effects on post-ischemic recovery of heart function and substrate oxidation in the diabetic rat. Mol Cell Biochem 2000; 206 (1-2): 151-7
5. Taylor PM. Absorbing competition for carnitine [letter]. J Physiol 2001; 532 (Pt 2): 283
6. Akar H, Sarac A, Konuralp C, et al. Comparison of histopathologic effects of carnitine and ascorbic acid on reperfusion injury. Eur J Cardiothorac Surg 2001; 19: 500-6
7. Hiatt WR. Current and future drug therapies for claudication. Vasc Med 1997; 2: 257-62
8. Terada R, Matsubara T, Koh N, et al. Effects of propionyl-L-carnitine on cardiac dysfunction in streptozotocin-diabetic rats. Eur J Pharmacol 1998; 357: 185-91
9. Corsico N, Nardone A, Lucreziotti MR, et al. Effect of propionyl-L-carnitine in a rat model of peripheral arteriopathy: a functional, histologic, and NMR spectroscopic study. Cardiovasc Drugs Ther 1993; 7: 241-51
10. Isner JM, Rosenfield K. Redefining the treatment of peripheral artery disease: role of percutaneous revascularization. Circulation 1993; 88 (4 Pt 1): 1534-57
11. Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication, and risk of cardiovascular events. Diabetes 1989; 38: 504-9
12. Beach KW, Strandness DE. Arteriosclerosis obliterans and associated risk factor in insulin dependent and non-insulin-dependent diabetes. Diabetes 1980; 29: 882-8
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type II diabetes (UKPDS 33). Lancet 1998; 352: 837-53
14. Diabetes Control and Complication Trial (DCCT). Effect of intensive diabetes management on macrovascular events and risk factors. Am J Cardiol 1995; 75: 894-903
15. Bremer J. Carnitine-metabolism and function. Physiol Rev 1983; 63: 1420-80
16. Bieber LL, Emaus R, Valkner K, et al. Possible function of short-chain and medium-chain carnitine acyltransferase. Fed Proc 1982; 41: 2858-62
17. Brass EP, Hoppel CL. Relationship between acid soluble carnitine and coenzyme A pools in vivo. Biochem J 1980; 190: 495-504
18. Genuth SM, Hoppel CM. Plasma and urine carnitine in diabetic ketoacidosis. Diabetes 1979; 28: 1083-7
19. Hoppel CM, Genuth SM. Carnitine metabolism in normal-weight and obese human subjects. Am J Physiol 1980; 238: E409-15
20. Carlin GI, Reddan WG, Sanjak M, et al. Carnitine metabolism during prolonged exercise and recovery in humans. J Appl Physiol 1986; 61: 1275-8
21. Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol 1987; 62: 2383-7
22. Brevetti G, Perna S, Sabbà C. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity patients with peripheral vascular disease: an acute, intravenous, double-bind, crossover study. Eur Heart J 1992; 13: 251-5
23. Chance B, Sies H, Boveris H. Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979; 59: 527-605
24. Mugge A, Elwell GH, Peterson TE, et al. Release of intact endothelium derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol 1991; 260: 1660-6
25. Di Lisa F, Menabo R, Silirandi L. L-propionylcarnitine protection of mitochondria in ischemic rat hearts. Mol Cell Biochem 1989; 88: 169-73
26. Van Hinsberg VWM, Scheffler MA. Effect of L-propionyl-carnitine on human endothelial cells. Cardiovasc Drugs Ther 1991; 5: 97-105
27. Cittanti C, Colamussi P, Giganti M, et al. Technetium-99m sestamibi leg scintigraphy for non-invasive assessment of propionyl-L-carnitine induced changes in skeletal muscle metabolism. Eur J Nucl Med 1997; 24: 762-6
28. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with vascular disease treated with L-carnitine: a double-bind, crossover study. Circulation 1988; 177: 767-73
29. Brevetti G, Angelini C, Rosa M, et al. Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991; 84: 1490-5